270
Participants
Start Date
March 31, 2011
Primary Completion Date
April 30, 2014
Study Completion Date
July 31, 2014
D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV
Single IV dose of aspirin at a dose of 500 mg as bolus infusion injection in approximately 30 seconds through the vein on Day 1.
D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 250 mg IV
Single IV dose of aspirin at a dose of 250 mg as bolus infusion injection in approximately 30 seconds through the vein on Day 1.
Acetylsalicylic acid (Aspirin, BAYe4465) 300 mg Tablet
Single oral dose of aspirin tablet at a dose of 300 mg on Day 1.
Berlin
Melsungen
Magdeburg
Mönchengladbach
Essen
Valencia
Cologne
Bonn
Mainz
Soest
Ludwigshafen am Rhein
Worms
Heidelberg
Bad Krozingen
Dachau
Coburg
Beijing
Beijing
Moscow
Shenyang
Shenyang
Moscow
Moscow
Moscow
Moscow
Moscow
Shanghai
Hangzhou
Nanchang
Changsha
Guangzhou
Guangzhou
Guangzhou
Guangzhou
Alicante
San Juan
Sabadell
Lead Sponsor
Bayer
INDUSTRY